Lingzhi Hong
机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0001-6553-3279
发表论文 278 篇 · 总被引 2884 次 · h-index 26
代表论文
- Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs (2026 · Journal of Thoracic Oncology · 被引 9)
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance (2026 · Cell · 被引 3)
- PP01.23/OA07.01: Myeloid IL-1 Signaling Drives The Precancer-to-Cancer Evolution of Human Pulmonary Nodules (2026 · Journal of Thoracic Oncology · 被引 1)
- Data from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco (2026)
- Supplementary Data1 from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco (2026)
- HER2 mutation–derived neoantigens in NSCLC as actionable targets for TCR therapy (2026 · bioRxiv (Cold Spring Harbor Laboratory))